Peptide vaccine candidates against classical swine fever virus: T cell and neutralizing antibody responses of dendrimers displaying E2 and NS2-3 epitopes

Journal of Peptide Science

Volumn 17, Issue 1, 2011, Pages 24-31

  Monsó, Marta ^a   Tarradas, Joan ^b   De La Torre, Beatriz G ^a   Sobrino, Francisco ^c   Ganges, Llilianne ^b   Andreu, David ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Classical swine fever; Dendrimeric peptides; PEG like flexibilizing units; Peptide vaccines

Indexed keywords

DENDRIMER; EPITOPE; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; SWINE FEVER VIRUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; DRUG DESIGN; DRUG SCREENING; HOST; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PESTIVIRUS; PRIORITY JOURNAL; SWINE; T LYMPHOCYTE; VACCINE PRODUCTION; VIRUS IMMUNITY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; CLASSICAL SWINE FEVER; CLASSICAL SWINE FEVER VIRUS; CYSTEINE ENDOPEPTIDASES; DENDRIMERS; EPITOPES; MOLECULAR SEQUENCE DATA; PEPTIDES; SWINE; T-LYMPHOCYTES; VIRAL VACCINES;

CLASSICAL SWINE FEVER VIRUS; SUIDAE; SUS SCROFA DOMESTICA;

EID: 78650253836     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1292     Document Type: Article

References (55)

1. Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. USA 1988; 85: 5409-5413.
2. Mezö G, de Oliveira E, Krikorian D, Feijlbrief M, Jakab A, Tsikaris V, Sakarellos C, Welling-Wester S, Andreu D, Hudecz F. Synthesis and comparison of antibody recognition of conjugates containing herpes simplex virus type 1 glycoprotein D epitope VII. Bioconjug. Chem. 2003; 14: 1260-1269.
3. Krikorian D, Stavrakoudis A, Biris N, Sakarellos C, Andreu D, de Oliveira E, Mezö G, Majer Z, Hudecz F, Welling-Wester S, Cung MT, Tsikaris V. Influence of sequential oligopeptide carriers on the bioactive structure of conjugated epitopes: comparative study of the conformation of a herpes simplex virus glycoprotein gD-1 epitope in the free and conjugated form, and protein "built-in" crystal structure. Biopolymers 2006; 84: 383-399.
4. Borrás-Cuesta F, Fedon Y, Petit-Camurdan A. Enhancement of peptide immunogenicity by linear polymerization. Eur. J. Immunol. 1988; 18: 199-202.
5. Tsikaris V, Sakarellos C, Cung MT, Marraud M, Sakarellos-Daitsiotis M. Concept and design of a new class of sequential oligopeptide carriers (SOC) for covalent attachment of multiple antigenic peptides. Biopolymers 1996; 38: 291-293.
6. Kragol G, Otvos L. Orthogonal solid-phase synthesis of tetramannosylated peptide constructs carrying three independent branched epitopes. Tetrahedron 2001; 57: 957-966.
7. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L, Gerhard W. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003; 21: 2616-2626.
8. Tam JP. Recent advances in multiple antigen peptides. J. Immunol. Methods 1996; 196: 17-32.
9. Lee CC, MacKay JA, Fréchet JM, Szoka FC. Designing dendrimers for biological applications. Nat. Biotechnol. 2005; 23: 1517-1526.
10. Tam JP, Lu YA, Yang JL. Antimicrobial dendrimeric peptides. Eur. J. Biochem. 2002; 269: 923-932.
11. Pini A, Falciani C, Bracci L. Branched peptides as therapeutics. Curr. Protein Pept. Sci. 2008; 9: 468-477.
12. Pini A, Giuliani A, Falciani C, Runci Y, Ricci C, Lelli B, Malossi M, Neri P, Rossolini GM, Bracci L. Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob. Agents Chemother. 2005; 49: 2665-2672.
13. Cubillos C, de la Torre BG, Jakab A, Clementi G, Borràs E, Bárcena J, Andreu D, Sobrino F, Blanco E. Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide. J. Virol. 2008; 82: 7223-7230.
14. Dong XN, Chen YH. Marker vaccine strategies and candidate CSFV marker vaccines. Vaccine 2007; 25: 205-230.
15. Ganges L, Barrera M, Núñez JI, Blanco I, Frías MT, Rodríguez F, Sobrino F. A DNA vaccine expressing the E2 protein of classical swine fever virus elicits T cell responses that can prime for rapid antibody production and confer total protection upon viral challenge. Vaccine 2005; 23: 3741-3752.
16. Kimman TG, Bianchi AT, Wensvoort G, de Bruin TG, Meliefste C. Cellular immune response to hog cholera virus (HCV): T cells of immune pigs proliferate in vitro upon stimulation with live HCV, but the E1 envelope glycoprotein is not a major T-cell antigen. J. Virol. 1993; 67: 2922-2927.
17. Summerfield A, Knötig SM, McCullough KC. Lymphocyte apoptosis during classical swine fever: implication of activation-induced cell death. J. Virol. 1998; 72: 1853-1861.
18. Summerfield A, Knoetig SM, Tschudin R, McCullough KC. Pathogenesis of granulocytopenia and bone marrow atrophy during classical swine fever involves apoptosis and necrosis of uninfected cells. Virology 2000; 272: 50-60.
19. Beer M, Reimann I, Hoffmann B, Depner K. Novel marker vaccines against classical swine fever. Vaccine 2007; 25: 5665-5670.
20. van Zijl M, Wensvoort G, de Kluyver E, Hulst M, van der Gulden H, Gielkens A, Berns A, Moormann R. Live attenuated pseudorabies virus expressing envelope glycoprotein E1 of hog cholera virus protects swine against both pseudorabies and hog cholera. J. Virol. 1991; 65: 2761-2765.
21. Hulst MM, Westra DF, Wensvoort G, Moormann RJ. Glycoprotein E1 of hog cholera virus expressed in insect cells protects swine from hog cholera. J. Virol. 1993; 67: 5435-5442.
22. König M, Lengsfeld T, Pauly T, Stark R, Thiel HJ. Classical swine fever virus: independent induction of protective immunity by two structural glycoproteins. J. Virol. 1995; 69: 6479-6486.
23. Andrew ME, Morrissy CJ, Lenghaus C, Oke PG, Sproat KW, Hodgson AL, Johnson MA, Coupar BE. Protection of pigs against classical swine fever with DNA-delivered gp55. Vaccine 2000; 18: 1932-1938.
24. Harpin S, Talbot B, Mbikay M, Elazhary Y. Immune response to vaccination with DNA encoding the bovine viral diarrhea virus major glycoprotein gp53 (E2). FEMS Microbiol. Lett. 1997; 146: 229-234.
25. Yu X, Tu C, Li H, Hu R, Chen C, Li Z, Zhang M, Yin Z. DNA-mediated protection against classical swine fever virus. Vaccine 2001; 19: 1520-1525.
26. Nobiron I, Thompson I, Brownlie J, Collins ME. DNA vaccination against bovine viral diarrhoea virus induces humoral and cellular responses in cattle with evidence for protection against viral challenge. Vaccine 2003; 21: 2082-2092.
27. Liang R, van den Hurk JV, Zheng C, Yu H, Pontarollo RA, Babiuk LA, van Drunen Littel-van den Hurk S. Immunization with plasmid DNA encoding a truncated, secreted form of the bovine viral diarrhea virus E2 protein elicits strong humoral and cellular immune responses. Vaccine 2005; 23: 5252-5262.
28. Wienhold D, Armengol E, Marquardt A, Marquardt C, Voigt H, Büttner M, Saalmüller A, Pfaff E. Immunomodulatory effect of plasmids co-expressing cytokines in classical swine fever virus subunit gp55/E2-DNA vaccination. Vet. Res. 2005; 36: 571-587.
29. Andrew M, Morris K, Coupar B, Sproat K, Oke P, Bruce M, Broadway M, Morrissy C, Strom D. Porcine interleukin-3 enhances DNA vaccination against classical swine fever. Vaccine 2006; 24: 3241-3247.
30. Hooft van Iddekinge BJ, de Wind N, Wensvoort G, Kimman TG, Gielkens AL, Moormann RJ. Comparison of the protective efficacy of recombinant pseudorabies viruses against pseudorabies and classical swine fever in pigs; influence of different promoters on gene expression and on protection. Vaccine 1996; 14: 6-12.
31. Mulder WA, Priem J, Glazenburg KL, Wagenaar F, Gruys E, Gielkens AL, Pol JM, Kimman TG. Virulence and pathogenesis of nonvirulent and virulent strains of pseudorabies virus expressing envelope glycoprotein E1 of hog cholera virus. J. Gen. Virol. 1994; 75: 117-124.
32. Peeters B, Bienkowska-Szewczyk K, Hulst M, Gielkens A, Kimman T. Biologically safe, nontransmissible pseudorabies virus vector vaccine protects pigs against both Aujeszky's disease and classical swine fever. J. Gen. Virol. 1997; 78: 3311-3315.
33. Hammond JM, McCoy RJ, Jansen ES, Morrissy CJ, Hodgson AL, Johnson MA. Vaccination with a single dose of a recombinant porcine adenovirus expressing the classical swine fever virus gp55 (E2) gene protects pigs against classical swine fever. Vaccine 2000; 18: 1040-1050.
34. van Gennip HG, van Rijn PA, Widjojoatmodjo MN, de Smit AJ, Moormann RJ. Chimeric classical swine fever viruses containing envelope protein E(RNS) or E2 of bovine viral diarrhoea virus protect pigs against challenge with CSFV and induce a distinguishable antibody response. Vaccine 2000; 19: 447-459.
35. de Smit AJ, Bouma A, de Kluijver EP, Terpstra C, Moormann RJ. Duration of the protection of an E2 subunit marker vaccine against classical swine fever after a single vaccination. Vet. Microbiol. 2001; 78: 307-317.
36. Reimann I, Depner K, Trapp S, Beer M. An avirulent chimeric Pestivirus with altered cell tropism protects pigs against lethal infection with classical swine fever virus. Virology 2004; 322: 143-157.
37. Dong XN, Chen Y, Wu Y, Chen YH. Candidate multi-peptide-vaccine against classical swine fever virus induced potent immunity with serological marker. Vaccine 2005; 23: 3630-3633.
38. Dong XN, Chen YH. Candidate peptide-vaccines induced immunity against CSFV and identified sequential neutralizing determinants in antigenic domain A of glycoprotein E2. Vaccine 2006; 24: 1906-1913.
39. Dong XN, Chen YH. Spying the neutralizing epitopes on E2 N-terminal by candidate epitope-vaccines against classical swine fever virus. Vaccine 2006; 24: 4029-4034.
40. Dong XN, Qi Y, Ying J, Chen X, Chen YH. Candidate peptide-vaccine induced potent protection against CSFV and identified a principal sequential neutralizing determinant on E2. Vaccine 2006; 24: 426-434.
41. Dong XN, Wei K, Liu ZQ, Chen YH. Candidate peptide vaccine induced protection against classical swine fever virus. Vaccine 2002; 21: 167-173.
42. Liu S, Tu C, Wang C, Yu X, Wu J, Guo S, Shao M, Gong Q, Zhu Q, Kong X. The protective immune response induced by B cell epitope of classical swine fever virus glycoprotein E2. J. Virol. Methods 2006; 134: 125-129.
43. Lin M, Lin F, Mallory M, Clavijo A. Deletions of structural glycoprotein E2 of classical swine fever virus strain alfort/187 resolve a linear epitope of monoclonal antibody WH303 and the minimal N-terminal domain essential for binding immunoglobulin G antibodies of a pig hyperimmune serum. J. Virol. 2000; 74: 11619-11625.
44. Armengol E, Wiesmüller KH, Wienhold D, Büttner M, Pfaff E, Jung G, Saalmüller A. Identification of T-cell epitopes in the structural and non-structural proteins of classical swine fever virus. J. Gen. Virol. 2002; 83: 551-560.
45. Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 1990; 35: 161-214.
46. Terpstra C, Bloemraad M, Gielkens AL. The neutralizing peroxidase-linked assay for detection of antibody against swine fever virus. Vet. Microbiol. 1984; 9: 113-120.
47. Tarradas J, Argilaguet JM, Rosell R, Nofrarias M, Crisci E, Córdoba L, Pérez-Martín E, Díaz I, Rodríguez F, Domingo M, Montoya M, Ganges L. Interferon-gamma induction correlates with protection by DNA vaccine expressing E2 glycoprotein against classical swine fever virus infection in domestic pigs. Vet. Microbiol. 2010; 142: 51-58.
48. Van Noort JM, Boon J, Van der Drift AC, Wagenaar JP, Boots AM, Boog CJ. Antigen processing by endosomal proteases determines which sites of sperm-whale myoglobin are eventually recognized by T cells. Eur. J. Immunol. 1991; 21: 1989-1996.
49. Kowalczyk W, de la Torre BG, Andreu D. Strategies and limitations in dendrimeric immunogen synthesis. The influenza virus M2e epitope as a case study. Bioconjug. Chem. 2010; 21: 102-110.
50. Galande AK, Hilderbrand SA, Weissleder R, Tung CH. Enzyme-targeted fluorescent imaging probes on a multiple antigenic peptide core. J. Med. Chem. 2006; 49: 4715-4720.
51. De la Torre B, Jakab A, Andreu D. Polyethyleneglycol-based resins as solid supports for the synthesis of difficult or long peptides. Int. J. Pept. Res. Ther. 2007; 13: 265-270.
52. García-Martín F, Quintanar-Audelo M, García-Ramos Y, Cruz LJ, Gravel C, Furic R, Côté S, Tulla-Puche J, Albericio F. ChemMatrix, a poly(ethylene glycol)-based support for the solid-phase synthesis of complex peptides. J. Comb. Chem. 2006; 8: 213-220.
53. Terpstra C, Wensvoort G. The protective value of vaccine-induced neutralising antibody titres in swine fever. Vet. Microbiol. 1988; 16: 123-128.
54. Van Rijn PA, Bossers A, Wensvoort G, Moormann RJ. Classical swine fever virus (CSFV) envelope glycoprotein E2 containing one structural antigenic unit protects pigs from lethal CSFV Challenger. J. Gen. Virol. 1996; 77: 2737-2745.
55. Bouma A, de Smit AJ, de Kluijver EP, Terpstra C, Moormann RJ. Efficacy and stability of a subunit vaccine based on glycoprotein E2 of classical swine fever virus. Vet. Microbiol. 1999; 66: 101-114.